# A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

> **NCT07143292** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 120 (estimated)

## Conditions studied

- Cervical Cancer Metastatic
- Cervical Cancer Recurrent

## Interventions

- **DRUG:** Famitinib + Camrelizumab

## Key facts

- **NCT ID:** NCT07143292
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07143292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07143292, "A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07143292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*